Shield Therapeutics
LONDON, October 12, 2011 -
- Two pivotal trials initiated for treatment of iron deficiency anaemia associated with ulcerative colitis and Crohn's disease -
Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease (IBD).
LONDON, June 1, 2011 -
- New Investment to Further Fund the Phase III Clinical Programme of
ST10-021 in Iron Deficiency Anaemia
Shield Therapeutics (Shield), the independent specialty
pharmaceutical company focused on the development and commercialisation of
late-stage hospital pharmaceuticals, today announces that it has successfully
raised EUR8.2m (CHF10m/US$12m) from Inventages Venture Capital (Inventages)
in its first institutional (Series A) financing round.
WOLLERAU, Switzerland, January 7, 2011 - Shield Holdings AG (Shield), the independent specialty
pharmaceutical company focused on the development and commercialisation of
late-stage hospital pharmaceuticals, today announces that Carl Sterritt,
Chief Executive Officer, will present at the Biotech Showcase Conference on
Wednesday 12 January, 2011 at 14:30 PST/ 22:30 GMT at the Parc 55 Wyndham
Union Square Hotel in San Francisco, California.
WOLLERAU, Switzerland, November 1, 2010 - Shield Holdings AG (Shield), the independent specialty
pharmaceutical company focused on the development and commercialisation of
late-stage hospital pharmaceuticals, today announces that it has signed a
strategic commercialisation agreement for its lead asset, ST10-021, an iron
therapy product which has commenced Phase III clinical development, with AOP
Orphan Pharmaceuticals AG ("AOP").
